Dementia Drugs Market Size is projected to reach USD 26,795.69 million by 2030, growing at a CAGR of 7.95%: Straits Research
April 08, 2024 10:15 ET
|
Straits Research Private Limited - Reed Intelligence
New York, United States, April 08, 2024 (GLOBE NEWSWIRE) -- Dementia is a term used to describe a group of symptoms that significantly impair memory, reasoning, and social abilities. The symptoms...
Neurology Contract Research Organization Market Poised for Expansion, Forecasts Indicate Robust Growth by 2031
January 31, 2024 08:08 ET
|
Research and Markets
Dublin, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The "Neurology Contract Research Organization Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology,...
Neurology Patient Monitoring Market Analysis Reaches Unprecedented Growth by 2030
January 25, 2024 14:53 ET
|
Research and Markets
Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Global Neurology Patient Monitoring Market by Device (Cerebral Oximeters, Electroencephalography Monitors, Intracranial Pressure Monitors), Disease...
Axial Therapeutics to Present at Upcoming Conferences
January 05, 2024 08:05 ET
|
Axial Therapeutics
WOBURN, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Axial Therapeutics, a clinical-stage biotechnology company dedicated to the development of gut-targeted, small molecule therapeutics for neurological...
Global Nerve Repair and Regeneration Devices Strategic Business Report 2023: Intensified Research Activity Across Various Neural Disciplines Induces Additional Optimism
June 21, 2023 04:23 ET
|
Research and Markets
Dublin, June 21, 2023 (GLOBE NEWSWIRE) -- The "Nerve Repair and Regeneration Devices: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market...
Axial Therapeutics Receives Second Research Grant Award from The Michael J. Fox Foundation to Further Support Advancement of AX-5006 for Parkinson’s Disease
June 20, 2023 08:00 ET
|
Axial Therapeutics
–Grant supports the continued preclinical development of AX-5006, a small molecule, gut-restricted amyloid inhibitor for symptomatic treatment and modification of disease in PD– –IND-enabling...
Global Immunoassay for Neurological Biomarkers Market to 2030: Increasing Prevalence of Neurological Diseases Fuels the Sector
June 05, 2023 05:08 ET
|
Research and Markets
Dublin, June 05, 2023 (GLOBE NEWSWIRE) -- The "Immunoassay for Neurological Biomarkers Market Size, Share & Trends Analysis Report By Product, By Disease (Alzheimer's Disease, Parkinson's...
Axial Therapeutics Announces Key Research and Development Promotions to Advance Clinical and Preclinical Pipeline of Small Molecule Microbiome Therapeutics
March 29, 2023 08:00 ET
|
Axial Therapeutics
– Phase 2b clinical trial for AB-2004 in autism irritability ongoing and enrollment anticipated to be complete by end of 2023 – – IND-enabling studies ongoing for Parkinson’s Disease development...
Clinical ink Selected for Global Late Phase Parkinson’s Disease Programs
December 15, 2022 08:42 ET
|
Clinical Ink
Horsham, PA, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Clinical ink, a global life science technology company, has partnered with a leading biopharmaceutical organization focused on Parkinson’s Disease...
H2o Therapeutics Gets FDA Clearance for Its Apple Watch-Based App for Parkinson's Disease
November 20, 2022 09:01 ET
|
h2o therapeutics
ANKARA, Turkey, Nov. 20, 2022 (GLOBE NEWSWIRE) -- Digital health start-up H2o therapeutics received 510(k) marketing clearance from the U.S. Food and Drug Administration for its prescription mobile...